CareFusion will acquire GE Healthcare’s Vital Signs division.
CareFusion has signed a definitive agreement to acquire the Vital Signs division of GE Healthcare for $500 million, CareFusion announced in a press release. Vital Signs manufactures single-patient-use consumables for respiratory care and anesthesiology. The acquisition will expand CareFusion's Specialty Disposables business by adding global scale and new products for anesthesiology.
CareFusion expects the acquisition to advance its goal of expanding in international markets. The acquisition will accelerate the transformation of the Specialty Disposables business from a distributor to a vertically integrated manufacturer. With the addition of the Vital Signs portfolio, CareFusion will become a full-line provider of more than 20,000 single-use consumables for respiratory care and anesthesiology, including circuits for oxygen and anesthesia, humidification, masks, filters, pressure infusers, and temperature-management products.
The acquisition is expected to be completed for the Vital Signs business in the United States, China and certain other countries by Dec. 31, 2013. The company expects to finalize the remainder of the transaction during its third quarter, ending March 31, 2014, subject to regulatory review and customary closing conditions. Headquartered in Totowa, New Jersey, Vital Signs has more than 1000 employees in three primary locations worldwide, including manufacturing operations in Shenzhen, China, and a global, field-based sales organization.
Source: CareFusion
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.